Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing
04/05/2026 21:31
May 4 (Reuters) - Damora Therapeutics Inc DMRA.O: DAMORA THERAPEUTICS INC - LORI FIRMANI TO CEASE SERVING AS CFO EFFECTIVE MAY 1, 2026 - SEC FILING DAMORA THERAPEUTICS INC - APPOINTS BRIAN BURKAVAGE AS PRINCIPAL FINANCIAL OFFICER EFFECTIVE MAY 1, 2026 - SEC FILING Source text: [ID:n0001193125-26-203913] Further company coverage: DMRA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Damora Therapeutics
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. RESEARCH ROUNDUP-Blackstone, Hartford Insurance, Zevra Therapeutics
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
Brief: Damora Therapeutics Reports First Quarter 2026 Financial Results
Brief: Damora Therapeutics: Lori Firmani To Cease Serving As CFO Effective May 1, 2026 - SEC Filing